EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration

Subgroup analyses underscore favorable clinical profile and durability of EYP-1901Presentations highlight previously reported positive Phase 2 DAVIO 2 topline results showing all primary and secondary...

Related Keywords

Texas ,United States ,Macao ,Macau General ,Macau ,Massachusetts ,China ,Hong Kong ,Taiwan ,Watertown ,Carl Regillo ,Jay Duker ,Christina Tartaglia ,Charlesc Wykoff ,Amy Phillips ,Globenewswire Inc ,Eyepoint Pharmaceuticals Nasdaq ,Thomas Jefferson University ,Eyepoint Pharmaceuticals Inc ,Exchange Commission ,Equinox Sciences ,Eyepoint Pharmaceuticals ,Green Room Communications ,Drug Administration ,Nasdaq ,Point Pharmaceuticals ,Chief Executive Officer ,Private Securities Litigation Reform Act ,Markets ,